



Mechanical thrombectomy with a novel stent retriever with multifunctional zones: Initial Clinical Experience with the NeVa™ thrombectomy device

M. RIBO, J. MACHO, J. ZAMARRO, P. MACHI, D. HERNANDEZ, J. BLASCO, A. TOMASELLO

First in Man study: retrospective analysis of the first 30 consecutive patients treated with the NeVa™ device as first line therapy in 4 centers (Clinic Barcelona, Vall d'Hebron Hospital, Murcia Hospital, University Hospital of Geneva)


Baseline Information – 30 Patients

Mean Age: 72
Mean NIHSS at admission: 16
ASPECTS: > 5
IV Thrombolysis: 40%
Occlusion site:

3% Basilar


53% Left } 10% Extra-cranial
44% Right } 23% ICA T
54% M1
10% M2

Workflow Information




First Pass TICl Scores with NeVa

TICl 2C/3 14/30 **47%**
TICl 2B+ 19/30 **63%**



Final TICl Scores with NeVa


TICl 2C/3 19/30 **63%**
TICl 2B+ 28/30 **93%**



Average # of passes for final recan → 1.7

Discussion


In the 40 passes where the info was available: 70% clot incorporation into device basket



NeVa was effective with both balloon guide and local aspiration strategies

Patient Outcomes

Mean NIHSS @ 24hr: 7
90 day mRS < 2 : 53%



Zero NeVa related adverse events & sICH

Conclusion

- NeVa has high 1st pass success
- Good safety profile
- Favorable outcomes